Drug intelligence / Profile preview

CLM124

Development stage: Preclinical
Lead developer: Mayo Clinic
Modality: Small Molecules

Overview

CLM124 (also known as CLM-124) is a novel, specific retinoic acid receptor gamma (RARγ) agonist being developed as an anti-resorptive therapy for osteoporosis. Developed by researchers at the Mayo Clinic, CLM124 acts by suppressing osteoclast differentiation and bone resorption while maintaining osteoclast-osteoblast coupling and preserving physiological bone remodeling. In preclinical models, CLM124 has demonstrated efficacy in mitigating bone loss induced by whole limb radiation and ovariectomy.

Targets

RARG (Retinoic acid receptor gamma)

Beyond the preview

Go deeper on CLM124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLM124.